Under the joint development agreement, Philips will support Profound Medical’s proprietary transurethral ultrasound ablation (TULSA) technology to treat patients with prostate cancer on its Ingenia and Achieva 3T MRI systems.

Profound’s TULSA technology is a single session procedure that is emerging as a new minimally invasive and whole gland ablation of the prostate.

Profound Medical CEO Steve Plymale said: "Philips has stepped forward and enthusiastically shares our vision for the technology.
With their support, TULSA-PRO will soon be available to clinicians and patients for primary treatment of localized prostate cancer.

"This new relationship will provide us with access to a large installed base of MRI systems and customers and we look forward to developing this mutually rewarding relationship further."

Profound Medical plans to release TULSA-PRO’s 12 month data from its 30 patient safety and feasibility study. This data will be used to obtain CE mark approval and commercialize it in Europe and Canada in 2016.